PGN-EDO51

N/A

Report date: 2026/04/14 20:00:15

NME

Base Information

Drug NamePGN-EDO51

Drug Alias NamePGN EDO51PGN-EDO51EDO-51PGN-EDO23

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Peptide-oligonucleotide ConjugateSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) > Peptide-oligonucleotide Conjugate

Mechanisms of ActionRNA interferenceRNA splicing modulatorsDystrophin expression stimulants

TargetsDystrophin

Therapy Area/IndicationsMuscular Dystrophy, Duchenne

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPepgen Corp

China Registration ClassN/A

Develop Information

Active CompaniesPepgen Corp

Inactive CompaniesPepGen Inc

Active IndicationsMuscular Dystrophy, Duchenne

Inactive IndicationsN/A

Other Information

ATC CodeN/A